Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer

被引:20
|
作者
Shi, Qiuling [1 ]
Mendoza, Tito R. [1 ]
Wang, Xin Shelley [1 ]
Cleeland, Charles S. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, 1515 Holcombe Blvd,Unit 1450, Houston, TX 77030 USA
关键词
Patient-reported outcomes; Daily functioning; Cancer; Symptom-specific instrument; QUALITY-OF-LIFE; CELL LUNG-CANCER; RESPONSIVENESS; OUTCOMES; SURGERY; BURDEN; BREAST; RECOVERY; VALIDITY; CRITERIA;
D O I
10.1016/j.ejca.2016.07.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Improving, stable, or deteriorating patient functioning is critical to assess in cancer care and in oncology clinical trials. We evaluated the performance of the six-item interference subscale of the MD Anderson Symptom Inventory (MDASI) compared with two commonly used patient-reported measures of functioning as a reference: the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and the Medical Outcomes Study Short Form 12-item health survey (SF-12). Methods: In this secondary analysis of two databases, MDASI versus QLQ-C30 (431 multiple myeloma patients) and MDASI versus SF-12 in solid tumours (285 lung and 91 gastrointestinal cancer patients), we used Pearson correlations to test relationships of four SF-12 and five QLQ-C30 functioning subscales with MDASI total interference (MDASI-INTFER), physical (MDASI-WAW), and affective (MDASI-REM) subscales. We used area under the curve (AUC) to quantify ability to differentiate performance status levels, and Glass Delta effect size (ES) and standardised response mean to evaluate responsiveness to aggressive cancer treatment. Results: MDASI-WAW was strongly correlated with QLQ-C30 and SF-12 physical subscales across all three cancer types (all r >= 0.7, P < 0.0001). The MDASI-WAW displayed AUCs that were similar to the physical functioning scales of QLQ-C30 and SF-12 (>0.7). MDASI-WAW responsiveness was equivalent to the SF-12 physical functioning subscale for chemoradiotherapy (ES = 0.72 for MDASI-WAW; 0.55 for SF-12), surgery (ES = 0.92 for MDASI-WAW; 0.97 for SF-12), and worsening of general health (ES = 1.22 for MDASI-WAW; 1.05 for SF-12). Conclusions: MDASI interference is a valid measure of symptom-related functional impairment. The three-item MDASI-WAW subscale is comparable to the SF-12 in responsiveness to functional deterioration during aggressive cancer treatment. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:83 / 90
页数:8
相关论文
共 50 条
  • [1] A new symptom-specific patient-reported outcome measure for patients with soft tissue sarcoma
    Rentz, Anne
    Skalicky, Anne
    Ghate, Sameer
    Chawla, Sant P.
    Conley, Anthony P.
    Villalobos, Victor M.
    Perez, Jose Ricardo
    QUALITY OF LIFE RESEARCH, 2016, 25 : 123 - 123
  • [2] Development and Validation of a Visual Symptom-Specific Patient-Reported Outcomes Instrument for Adults With Cataract Intraocular Lens Implants
    Lasch, Kathryn
    Marcus, James C.
    Seo, Caroline
    McCarrier, Kelly P.
    Wirth, R. J.
    Patrick, Donald L.
    O'Riordan, John F.
    Stasaski, Renea
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2022, 237 : 91 - 103
  • [3] Patient-reported cognitive functioning and daily functioning in chronic dialysis patients
    Song, Mi-Kyung
    Ward, Sandra E.
    Bair, Eric
    Weiner, Lia J.
    Bridgman, Jessica C.
    Hladik, Gerald A.
    Gilet, Constance A.
    HEMODIALYSIS INTERNATIONAL, 2015, 19 (01) : 90 - 99
  • [4] Patient reported toxicities: Development and validation of patient-reported symptom measure for lung cancer patients receiving immunotherapy.
    Shaw, Sandra S.
    Jim, Heather S. L.
    Eisel, Sarah
    Hoogland, Aasha
    Leduc, David
    Dicker, Adam P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [5] Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study)
    Choo, M. -S.
    Doo, C. K.
    Lee, K. -S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (02) : 191 - 196
  • [6] Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer
    Shi, Qiuling
    Wang, Xin Shelley
    Vaporciyan, Ara A.
    Rice, David C.
    Popat, Keyuri U.
    Cleeland, Charles S.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 52 (06) : 822 - 831
  • [7] Development of a Cold Agglutinin Disease-Specific Patient-Reported Outcome Symptom Measure
    Joly, Florence
    Dasmahapatra, Pronabesh
    Su, Jun
    Di Benedetti, Dana
    Kosa, Katherina
    Hill, Quentin
    BLOOD, 2021, 138
  • [8] Using the Patient-Reported Outcomes Measurement Information System (PROMIS) to measure symptom burden reported by patients with brain tumors
    Lai, Jin-Shei
    Kupst, Mary Jo
    Beaumont, Jennifer L.
    Manley, Peter E.
    Chang, John Han-Chih
    Hartsell, William F.
    Kwok, Young
    Fisher, Allison Piazza
    Goldman, Stewart
    PEDIATRIC BLOOD & CANCER, 2019, 66 (03)
  • [9] Patient-reported care satisfaction and symptom burden in hospitalized patients with cancer
    Qian, Carolyn L.
    Vyas, Charu
    Gaufberg, Eva
    Kaslow-Zieve, Emilia
    Azoba, Chinenye C.
    Wang, Irene
    Van Seventer, Emily E.
    Newcomb, Richard
    Jackson, Vicki A.
    Ryan, David P.
    Greer, Joseph A.
    El-Jawahri, Areej
    Temel, Jennifer S.
    Nipp, Ryan David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [10] Generation of Symptom Burden Patient-Reported Outcomes for Patients with Lung Cancer
    Williams, L.
    Cleeland, C.
    Bamidele, O.
    Simon, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2023 - S2023